BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 26884885)

  • 21. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
    Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
    Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma].
    Ucvet A; Kul C; Gursoy S; Erbaycu AE; Kaya SO; Dinc ZA; Yucel N
    Arch Bronconeumol; 2011 Aug; 47(8):397-402. PubMed ID: 21696876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer.
    Iskender I; Kadioglu SZ; Cosgun T; Kapicibasi HO; Sagiroglu G; Kosar A; Kir A
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):874-9. PubMed ID: 22423060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
    Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
    Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
    Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
    J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.
    Ludovini V; Bellezza G; Pistola L; Bianconi F; Di Carlo L; Sidoni A; Semeraro A; Del Sordo R; Tofanetti FR; Mameli MG; Daddi G; Cavaliere A; Tonato M; Crinò L
    Ann Oncol; 2009 May; 20(5):842-9. PubMed ID: 19153117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
    Qiu ZX; Zhao S; Mo XM; Li WM
    Int J Clin Exp Pathol; 2015; 8(6):6589-95. PubMed ID: 26261540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
    Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
    Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer].
    Honguero Martínez AF; Arnau Obrer A; Figueroa Almazán S; Martínez Hernández N; Guijarro Jorge R
    Med Clin (Barc); 2014 May; 142(10):432-7. PubMed ID: 23948151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer.
    Qi H; Wang Y
    Clin Lab; 2018 Sep; 64(9):1469-1475. PubMed ID: 30274015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
    Xu XY; Lin N; Li YM; Zhi C; Shen H
    Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.